Publications
90
Citations
2,470
Est. group size
—
Recurring co-author estimate
Active years
18
Publishing since 2009
Niharika Samala is a medical researcher in hepatology, the study of the liver and its diseases. Her work focuses on fatty liver disease linked to metabolism (now called metabolic dysfunction-associated steatotic liver disease, or MASLD), including how it is diagnosed, monitored with imaging, and treated with newer drugs. She also studies liver disease in specific populations such as people with HIV, transgender and gender-diverse individuals, and women with polycystic ovary syndrome (PCOS).
Publication activity has been growing over the last decade, rising from around 4-5 per year in the late 2010s to 10-14 in recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Chronic liver disease and hepatology care in transgender and gender diverse populations
The Lancet. Gastroenterology & hepatology · 2026
- 2650-P: Multiorgan Magnetic Resonance–Based Imaging Improves Risk Stratification and Supports Treatment Allocation in Individuals with Clinical Obesity
Diabetes · 2026
- Early experience with resmetirom to treat metabolic dysfunction–associated steatohepatitis with fibrosis in a real-world setting
Hepatology Communications · 2025
- Reliable Monitoring of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Using Imaging: A Systematic Literature Review and Meta-Analysis on Measurement Repeatability
Endocrine Practice · 2025
- Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
Journal of Medical Economics · 2025
- THU-434 Liver phenotypes in a multicentric PCOS cohort: prospective analysis including steatotic liver disease-associated genetic variants
Journal of Hepatology · 2025
- Sa1488: LIVER TEST ELEVATION ASSOCIATED WITH GENDER-AFFIRMING HORMONE THERAPY IN TRANSGENDER AND GENDER-DIVERSE INDIVIDUALS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Gastroenterology · 2025
- SAT-668 Saroglitazar Improves Hepatic Steatosis And Liver Enzymes In Women With PCOS And MASLD: Results Of Evidences VII Randomized Control Study
Journal of the Endocrine Society · 2025
- Non-Hispanic Black Persons With Nonalcoholic Fatty Liver Disease Have Lower Rates of Advanced Fibrosis, Cirrhosis, and Liver-Related Events Even After Controlling for Clinical Risk Factors and PNPLA3 Genotype
The American Journal of Gastroenterology · 2024
- Associations between per- and polyfluoroalkyl substance exposures and metabolic dysfunction associated steatotic liver disease (MASLD) in adult National Health and Nutrition Examination Survey 2017 to 2018
Toxicological Sciences · 2024
- Association of cardiovascular disease risk with liver steatosis and fibrosis in people with HIV in low- and middle-income countries
AIDS · 2024
- S2011 Real-World Characteristics of the Patients With Metabolic Dysfunction-Associated Steatohepatitis Prescribed Resmetirom: Data Derived From Two Tertiary Care Centers in the United States
The American Journal of Gastroenterology · 2024
- Metabolic causes of liver disease among adults living with HIV from low‐ and middle‐income countries: a cross‐sectional study
Journal of the International AIDS Society · 2024
- Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Clinical Gastroenterology and Hepatology · 2023
- Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models
International Journal of Molecular Sciences · 2023
- The American Journal of Gastroenterology×10
- Gastroenterology×7
- Journal of Hepatology×7
- Clinical Gastroenterology and Hepatology×5
- Hepatology×4
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile